Fennec Pharma
A specialty pharmaceutical company focused on the development of Pedmark (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients.
As of December of 2021, the US Food and Drug Administration had twice rejected Fennec's attempts to gain approval for Pedmark due to production deficiencies.
Pedmark is the only drug candidate under clinical development in the US firm’s pipeline. In Europe, Fennec has submitted for marketing authorization to use the therapy under the trade name Pedmarqsi.
Latest Fennec Pharma News & Features
21 September 2022
30 November 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze